In contrast, with MCL, the prognostic significance of Ki-67 expression was not changed after the introduction of rituximab; the pooled HRs was 1.981 (95% CI: 1.099-3.569, p = 0.023) with rituximab and 3.123 (95% CI: 2.049-4.76, p = 0.000) without rituximab (Figure 5, Table 4). The gene discussed is MKI67; the disease is mantle cell lymphoma.